Changes in myocardial blood flow in a canine model of left sided breast cancer radiotherapy

PLoS One. 2023 Sep 28;18(9):e0291854. doi: 10.1371/journal.pone.0291854. eCollection 2023.

Abstract

Background: Left-sided breast cancer patients receiving adjuvant radiotherapy are at risk for coronary artery disease, and/or radiation mediated effects on the microvasculature. Previously our laboratory demonstrated in canines with hybrid 18FDG/PET a progressive global inflammatory response during the initial one year following treatment. In this study, the objective is to evaluate corresponding changes in perfusion, in the same cohort, where resting myocardial blood flow (MBF) was quantitatively measured.

Method: In five canines, Ammonia PET (13NH3) derived MBF was measured at baseline, 1-week, 1, 3, 6 and 12-months after cardiac external beam irradiation. MBF measurements were correlated with concurrent 18FDG uptake. Simultaneously MBF was measured using the dual bolus MRI method.

Results: MBF was significantly increased at all time points, in comparison to baseline, except at 3-months. This was seen globally throughout the entire myocardium independent of the coronary artery territories. MBF showed a modest significant correlation with 18FDG activity for the entire myocardium (r = 0.51, p = 0.005) including the LAD (r = 0.49, p = 0.008) and LCX (r = 0.47, p = 0.013) coronary artery territories.

Conclusion: In this canine model of radiotherapy for left-sided breast cancer, resting MBF increases as early as 1-week and persists for up to one year except at 3-months. This pattern is similar to that of 18FDG uptake. A possible interpretation is that the increase in resting MBF is a response to myocardial inflammation.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Breast Neoplasms*
  • Coronary Circulation / physiology
  • Dogs
  • Female
  • Fluorodeoxyglucose F18
  • Heart / diagnostic imaging
  • Humans
  • Myocardial Perfusion Imaging* / methods
  • Positron-Emission Tomography / methods
  • Unilateral Breast Neoplasms*

Substances

  • Fluorodeoxyglucose F18

Grants and funding